Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Specification of primary outcome measures for long-term safety and tolerability: Adverse events, blood pressure and heart rate, 12 lead ECG, clinical chemistry and hematology, Troponin I
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with CTEPH or PAH in NYHA class II or III
You may not be if
Patients with PDE 5 inhibitor or prostacycline pretreatment, relevant pulmonary diseases, relevant cardiac diseases, severe coagulation disorders, moderate to severe hepatic or renal insufficiency, pregnancy, hypotension
Clareo Health | An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension
